prazosin has been researched along with Dizzyness in 15 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Terazosin is an alpha1-selective adrenoceptor blocking agent that has been reported in many clinical trials to be an effective choice for the treatment of benign prostatic hyperplasia (BPH)." | 9.12 | Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan. ( Lan, SK; Ou, JH; Tsai, YS; Tzai, TS, 2007) |
| "The effect of withdrawal of terazosin therapy in patients with mild to moderate hypertension was assessed in two double-blind, placebo-controlled studies." | 9.06 | Effect of withdrawal of terazosin therapy in patients with hypertension. ( Ruoff, G, 1986) |
| "In this report, we assess the safety of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia." | 8.79 | Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. ( Lowe, FC; McKiernan, JM, 1997) |
| "Twelve patients with severe chronic congestive heart failure (CHF) (NYHA class III and IV) resistant to digitalis and diuretics were treated with the postsynaptic alpha-blocking agent prazosin (PZ) (3 to 20 mg/day)." | 7.66 | Sustained effectiveness of chronic prazosin therapy in severe chronic congestive heart failure. ( Bertel, O; Bühler, FR; Burkart, F, 1981) |
| "Terazosin is a selective alpha1-adrenoceptor antagonist." | 6.69 | Effects of oral and intravenous terazosin and head-up tilt on blood pressure responses in patients with hypertension. ( Achari, R; Baroldi, P; Cavanaugh, J; Cohen, A; Hosmane, B; Linnen, P, 1998) |
| "Terazosin is an alpha1-selective adrenoceptor blocking agent that has been reported in many clinical trials to be an effective choice for the treatment of benign prostatic hyperplasia (BPH)." | 5.12 | Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan. ( Lan, SK; Ou, JH; Tsai, YS; Tzai, TS, 2007) |
| "The effect of withdrawal of terazosin therapy in patients with mild to moderate hypertension was assessed in two double-blind, placebo-controlled studies." | 5.06 | Effect of withdrawal of terazosin therapy in patients with hypertension. ( Ruoff, G, 1986) |
| "In this report, we assess the safety of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia." | 4.79 | Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia. ( Lowe, FC; McKiernan, JM, 1997) |
| "Treatment of benign prostatic hyperplasia (BPH) with nonselective alpha1 antagonists such as terazosin, doxazosin, and prazosin results in blood pressure reduction due to vasodilation." | 3.71 | Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study. ( Chao, J; Chrischilles, E; Gilden, D; Kreder, KJ; Rubenstein, L; Shah, H, 2001) |
| "The safety of terazosin, an effective agent for the treatment of hypertension, was assessed by analyzing data from 1,006 hypertensive patients who were enrolled in short-term and/or long-term studies." | 3.67 | Overall safety of terazosin as an antihypertensive agent. ( Glassman, HN; Jordan, DC; Luther, RR; Sperzel, WD, 1986) |
| "Twelve patients with severe chronic congestive heart failure (CHF) (NYHA class III and IV) resistant to digitalis and diuretics were treated with the postsynaptic alpha-blocking agent prazosin (PZ) (3 to 20 mg/day)." | 3.66 | Sustained effectiveness of chronic prazosin therapy in severe chronic congestive heart failure. ( Bertel, O; Bühler, FR; Burkart, F, 1981) |
| "Mild dizziness/lightheadedness was more common in the TZ group, and three participants taking TZ dropped out because of dizziness and/or orthostatic hypotension." | 3.11 | A pilot to assess target engagement of terazosin in Parkinson's disease. ( Brinker, AN; Ernst, SE; Liu, L; Magnotta, VA; Narayanan, NS; Rauckhorst, AJ; Schultz, JL; Simmering, JE; Taylor, EB; Tayyari, F; Uc, EY; Welsh, MJ; Xu, J, 2022) |
| " Pharmacokinetic and pharmacodynamic modeling were performed subject by subject." | 2.73 | Pharmacokinetic and pharmacodynamic modelling of arterial haemodynamic effects of terazosin in healthy volunteers. ( Azanza, JR; Campanero, MA; Muñoz-Juarez, MJ; Quetglas, EG; Sádaba, B, 2008) |
| "Terazosin is a selective alpha1-adrenoceptor antagonist." | 2.69 | Effects of oral and intravenous terazosin and head-up tilt on blood pressure responses in patients with hypertension. ( Achari, R; Baroldi, P; Cavanaugh, J; Cohen, A; Hosmane, B; Linnen, P, 1998) |
| "dizziness and orthostatic hypotension)." | 2.40 | A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. ( Djavan, B; Marberger, M, 1999) |
| "Hypertension was induced by blockade of nitric oxide synthesis." | 1.33 | Experimental orthostasis elicits sustained hypertension, which can be prevented by sympathetic blockade in the rat. ( Dézsi, L; Kollai, M; Mészáros, M; Monos, E; Raffai, G, 2005) |
| "Prazosin was well tolerated except in one patient who experienced worsening angina." | 1.26 | Antihypertensive therapy with prazosin in patients with left ventricular dysfunction. Improvement in cardiac performance and exercise tolerance. ( Chan, S; Massie, BM, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (33.33) | 18.7374 |
| 1990's | 4 (26.67) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Schultz, JL | 1 |
| Brinker, AN | 1 |
| Xu, J | 1 |
| Ernst, SE | 1 |
| Tayyari, F | 1 |
| Rauckhorst, AJ | 1 |
| Liu, L | 1 |
| Uc, EY | 1 |
| Taylor, EB | 1 |
| Simmering, JE | 1 |
| Magnotta, VA | 1 |
| Welsh, MJ | 1 |
| Narayanan, NS | 1 |
| Belayneh, M | 1 |
| Korownyk, C | 1 |
| Raffai, G | 1 |
| Mészáros, M | 1 |
| Kollai, M | 1 |
| Monos, E | 1 |
| Dézsi, L | 1 |
| Tsai, YS | 1 |
| Lan, SK | 1 |
| Ou, JH | 1 |
| Tzai, TS | 1 |
| Campanero, MA | 1 |
| Sádaba, B | 1 |
| Muñoz-Juarez, MJ | 1 |
| Quetglas, EG | 1 |
| Azanza, JR | 1 |
| Bertel, O | 1 |
| Burkart, F | 1 |
| Bühler, FR | 1 |
| Massie, BM | 1 |
| Chan, S | 1 |
| Lepor, H | 1 |
| Theune, C | 1 |
| McKiernan, JM | 1 |
| Lowe, FC | 1 |
| Achari, R | 1 |
| Hosmane, B | 1 |
| Linnen, P | 1 |
| Cavanaugh, J | 1 |
| Baroldi, P | 1 |
| Cohen, A | 1 |
| Djavan, B | 1 |
| Marberger, M | 1 |
| Chrischilles, E | 1 |
| Rubenstein, L | 1 |
| Chao, J | 1 |
| Kreder, KJ | 1 |
| Gilden, D | 1 |
| Shah, H | 1 |
| Keusch, G | 1 |
| Weidmann, P | 1 |
| Glück, Z | 1 |
| Meier, A | 1 |
| Beretta-Piccoli, C | 1 |
| Ruoff, G | 1 |
| Sperzel, WD | 1 |
| Glassman, HN | 1 |
| Jordan, DC | 1 |
| Luther, RR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia[NCT03144596] | Phase 4 | 63 participants (Actual) | Interventional | 2015-10-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for prazosin and Dizzyness
| Article | Year |
|---|---|
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers.
Topics: Adrenergic alpha-Antagonists; Dizziness; Doxazosin; Humans; Hypotension; Lower Urinary Tract Symptom | 2016 |
Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Clinical Trials as Topic; Dizziness; Humans; | 1997 |
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Controlled Clinical Trials as Topic; Dizzines | 1999 |
6 trials available for prazosin and Dizzyness
| Article | Year |
|---|---|
A pilot to assess target engagement of terazosin in Parkinson's disease.
Topics: Adenosine Triphosphate; Dizziness; Humans; Parkinson Disease; Pilot Projects; Prazosin | 2022 |
Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cross-Over Studies; Dizziness; Drugs, Generic; Edema; | 2007 |
Pharmacokinetic and pharmacodynamic modelling of arterial haemodynamic effects of terazosin in healthy volunteers.
Topics: Abdominal Pain; Administration, Oral; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Anta | 2008 |
Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms.
Topics: Adrenergic alpha-Antagonists; Aged; Dizziness; Double-Blind Method; Female; Headache; Humans; Middle | 1995 |
Effects of oral and intravenous terazosin and head-up tilt on blood pressure responses in patients with hypertension.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Antihypertensive Agents; Blood Pressure; | 1998 |
Effect of withdrawal of terazosin therapy in patients with hypertension.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Clinical Trials as Topic; Dizziness; Female; Follow-Up | 1986 |
6 other studies available for prazosin and Dizzyness
| Article | Year |
|---|---|
Experimental orthostasis elicits sustained hypertension, which can be prevented by sympathetic blockade in the rat.
Topics: Animals; Blood Pressure; Chloralose; Dizziness; Heart Rate; Hypertension; Male; Prazosin; Rats; Rats | 2005 |
Sustained effectiveness of chronic prazosin therapy in severe chronic congestive heart failure.
Topics: Aged; Chronic Disease; Dizziness; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Pr | 1981 |
Antihypertensive therapy with prazosin in patients with left ventricular dysfunction. Improvement in cardiac performance and exercise tolerance.
Topics: Aged; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Dizziness; Exercise Test; Headache; | 1981 |
Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study.
Topics: Accidental Falls; Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Cohort Studies; Comor | 2001 |
[Prazosin in the combined treatment of moderate to severe hypertension].
Topics: Adrenergic beta-Antagonists; Body Weight; Diuretics; Dizziness; Drug Therapy, Combination; Female; H | 1979 |
Overall safety of terazosin as an antihypertensive agent.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Asthenia; Body Weight; Dizziness; Female; Hea | 1986 |